Nervous Disorder TRIZ Cases

Single variable domains displace chemokine ligands from CXCR7, resolving low immunogenicity and cross-reactivity challenges.

System xc- inhibitors modulate extracellular glutamate levels to prevent excitotoxicity and brain damage in addiction disorders.

Bridged bicyclic compounds target central M1 and M4 receptors to enhance cognitive function while avoiding peripheral side effects from M2 and M3 stimulation.

Segmenting antibodies into single variable domains improves therapeutic reliability while reducing off-target effects on unrelated proteins.

A monoclonal antibody binds the fatty acid binding pocket of adipocyte fatty acid-binding protein to neutralize its activity.

Engineered variable regions enable selective binding to amyloid-beta oligomers, avoiding monomer cross-reactivity that causes central side effects.

Alkylene bridges replace disulphide bonds in compstatin analogues, improving physicochemical stability and solubility while maintaining C3 binding efficacy.

Segmented microparticles with pH-dependent coatings accelerate alcohol metabolism and reduce cognitive impairment by targeting specific GI tract regions.

Optimized substituent patterns enhance metabolic stability and blood-brain barrier penetration for treating cognitive disorders.

Amino-sugar buffering neutralizes chitosan to create a thermogelling hydrogel that remains liquid at room temperature and gels at body heat.

Combining benzoxazole derivatives with antisense therapies stabilizes transthyretin proteins and reduces amyloid deposition.

Targeted genetic markers identify suicide risk via PCR analysis, resolving the trade-off between prediction reliability and testing complexity.

Tau-specific antibodies clear pathological aggregates from the brain, reducing toxicity and improving motor performance in mouse models.

Anti-Ryk antibodies block Wnt signaling to treat spinal cord injuries and neurodegenerative diseases.

Grafting undifferentiated neural stem cells into lesioned tissue promotes axonal extension and synaptic formation.

Human-derived monoclonal antibodies bind hyperphosphorylated Tau proteins to resolve diagnostic accuracy issues in neurodegenerative disease testing.

Segmented cover movement prevents accidental dose advancement during cleaning while ensuring precise powder delivery via a ratchet drive gear.

Aramchol salts with amino alcohols improve solubility and absorption for pharmaceutical formulations.

Formula I compounds treat neurodegenerative disorders by inhibiting toxic protein aggregation and promoting lysosomal clearance.

Oral precursors and Nrf2 activators bypass liver degradation to boost brain antioxidant defenses against stress.

Segmented pyridazine cores with variable substituents optimize efficacy against Huntington's disease.

A flowable carrier matrix enables minimally invasive delivery of wetted collagen sponge components through a cannula.

Medium chain triglyceride compositions reduce seizure frequency by at least 50% while improving dietary palatability compared to traditional ketogenic diets.

Administering GLI1 inhibitors recruits stem cells to form new myelin sheaths around demyelinated axons.

IL-15R agonists expand CD44+CD122+Kir+ CD8+ regulatory T cells, restoring self-tolerance and reducing autoantibody responses in autoimmune diseases.

Glycopyrrolate and mexiletine accelerate axonal regrowth to resolve slow regeneration rates.

Supplementing culture media with PDGFR agonists and thyroxine accelerates oligodendrocyte lineage differentiation from human induced pluripotent stem cells.

Small molecule combinations reprogram somatic cells into astrocytes, eliminating genetic alteration risks and reducing differentiation time.

N-benzhydryl quinuclidine derivatives selectively inhibit sodium leak channels to regulate cell excitability.

Intranasal basic rhEPO with low sialic acid content bypasses hepatic inactivation and reduces erythropoiesis risk while delivering effective neuron protection.

Fusion proteins combine bacteriophage g3p fragments with immunoglobulin Fc regions to reduce amyloid load and detect deposits in protein misfolding diseases.

Aluminum hydroxide damage-associated molecular pattern molecules boost nuclear reprogramming efficiency, reducing tumorigenic risks from integrating vectors.

Boronic acid conjugates modify morpholino oligonucleotides to resolve electrostatic repulsion and improve nuclease resistance.

Modified purine structures enhance A2A selectivity, reducing cardiovascular side effects while treating inflammation.

Bacterial extracellular vesicles deliver exRNA to downregulate inflammatory genes, reducing treatment duration and costs compared to standard therapies.

Diaryl hydrazone M1 promotes mitochondrial fusion to increase neuronal growth capacity and accelerate axon regeneration.

Optimized peptide sequences extend GLP-1 half-life by blocking rapid degradation, resolving short circulation time issues.

Engineered antibodies bind the cis-conformation of phosphorylated tau protein to neutralize pathogenic activity.

Segmented tricyclic pyrrolo derivatives target MPS1 and PIM1 kinases, reducing peripheral neuropathy from non-selective mitotic inhibitors.

Olive oil polyphenols protect stearidonic acid from oxidation while enabling efficient conversion to EPA and DHA for vegetarian diets.

A two-stage CD19xCD3 antibody dosage regimen adapts patients to therapy through progressive dose escalation.

Ligands bind MSRV-ENV proteins to modulate immune responses, addressing insufficient immunomodulatory effects in multiple sclerosis.

A GIP function inhibitor suppresses glucose-dependent insulinotropic polypeptide activity to improve motor control in aged individuals.

64Zn-enriched zinc aspartate improves cognitive functions and reduces amyloid levels in rat models.

Bacterial ribosome fractions induce somatic cell reprogramming, eliminating ethical concerns and cancerization risks associated with viral vectors.

CDIM binding proteins bind selectively to B cell epitopes, inducing cell death and increasing membrane permeability to enhance chemotherapeutic efficacy.

A 3.5:1 Dioscorea extract ratio stimulates endogenous nerve growth factor secretion, addressing side effects from recombinant protein administration.

A rivastigmine transdermal patch incorporates a saturated fatty acid to enhance skin permeation rates within the adhesive layer.

IGF1R-specific antibodies utilize receptor-mediated transcytosis to ferry therapeutic molecules across the blood-brain barrier.